The US regulator has granted another approval to New Jersey’s Merck & Co (NYSE: MRK), for Keytruda (pembrolizumab).
The approval, which covers people with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) is based on data from the Phase II KEYNOTE-629 trial.
A less common form of skin cancer, cSCC is associated with significant morbidity and a high cost of care, creating a significant impact on quality of life.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze